NexgenRx Balance Sheet Health
Financial Health criteria checks 6/6
NexgenRx has a total shareholder equity of CA$8.1M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$31.6M and CA$23.5M respectively. NexgenRx's EBIT is CA$479.8K making its interest coverage ratio 7.3. It has cash and short-term investments of CA$1.8M.
Key information
0%
Debt to equity ratio
CA$0
Debt
| Interest coverage ratio | 7.3x |
| Cash | CA$1.84m |
| Equity | CA$8.10m |
| Total liabilities | CA$23.49m |
| Total assets | CA$31.59m |
Recent financial health updates
No updates
Recent updates
Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking
May 21
We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 10NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues
Mar 14Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today
Mar 07Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?
Oct 18Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?
Nov 30What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You
Aug 24Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up
Jun 03NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 19
How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?
Dec 28Financial Position Analysis
Short Term Liabilities: NXG's short term assets (CA$25.3M) exceed its short term liabilities (CA$23.1M).
Long Term Liabilities: NXG's short term assets (CA$25.3M) exceed its long term liabilities (CA$394.6K).
Debt to Equity History and Analysis
Debt Level: NXG is debt free.
Reducing Debt: NXG has no debt compared to 5 years ago when its debt to equity ratio was 174.4%.
Debt Coverage: NXG has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NXG has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 06:08 |
| End of Day Share Price | 2025/01/28 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NexgenRx Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|